Program
calcipotriene
Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.
Its studies are mostly in Psoriasis · Alopecia Areata, led by 10 companies.
Drug pageCalcipotriene: every studyMany companies study it; this page follows only the 37 they lead. All 70 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LEO Pharmaits history only | 220 open or running | phase 4since Sep 15, 2005 | Sep 15, 2005 | none ahead |
| MC2 Therapeuticsits history only | 50 open or running | phase 3since Oct 9, 2017 | Oct 9, 2017 | none ahead |
| Almirallits history only | 20 open or running | phase 3since Nov 11, 2015 | Nov 11, 2015 | none ahead |
| Mayne Pharma International Ptyits history only | 20 open or running | phase 1since Mar 15, 2012 | Mar 15, 2012 | none ahead |
| Abbottits history only | 10 open or running | phase 3since Dec 12, 2007 | Dec 12, 2007 | none ahead |
| Egymedicalpediaits history only | 10 open or running | no phasesince Jun 23, 2023 | Jun 23, 2023 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 3since Jun 6, 2010 | Jun 6, 2010 | none ahead |
| Glenmark Pharmaceuticals Ltd. Indiaits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
| Huadong Medicineits history only | 10 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | none ahead |
| Tolmarits history only | 10 open or running | phase 1since Apr 6, 2017 | Apr 6, 2017 | none ahead |
Also a collaborator on its studies: Bioskin.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 23 studies since Sep 15, 2005.
- Mar 12, 2015Phase 2 study in Psoriasis VulgarisLEO Pharma · NCT02387853 · 117 enrolled · United States, Netherlands, Poland and more
- Nov 11, 2015Almirall’s first study: phase 3 study in Nail PsoriasisNew to AlmirallAlmirall · NCT02606760 · 378 enrolled · Bulgaria, Czechia, Germany and more
- Mar 9, 2017Phase 3 study in Nail PsoriasisAlmirall · NCT03079973 · United States
- Apr 6, 2017Tolmar’s first study: phase 1 study in Scalp PsoriasisNew to TolmarTolmar · NCT03122353 · 699 enrolled · United States
- Oct 9, 2017MC2 Therapeutics’ first study: phase 3 study in Psoriasis VulgarisNew to MC2 TherapeuticsMC2 Therapeutics · NCT03308799 · 794 enrolled · United States
- Nov 1, 2017Glenmark Pharmaceuticals Ltd. India’s first study: phase 3 study in Scalp PsoriasisNew to Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals Ltd. India · NCT03331523 · 643 enrolled · United States
- Feb 20, 2018Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03462927 · 63 enrolled · United States
- Nov 13, 2018Phase 1 study in VasoconstrictionMC2 Therapeutics · NCT03758365 · 36 enrolled · France
- Jan 10, 2019Phase 3 study in Psoriasis VulgarisMC2 Therapeutics · NCT03802344 · 498 enrolled · Czechia, Germany
- Jan 11, 2019Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03819218 · 7 enrolled · Czechia, Germany
- Mar 29, 2019Phase 1 study in Psoriasis VulgarisLEO Pharma · NCT03898583 · 15 enrolled · Germany
- Jun 16, 2023Phase 3 study in Stable Plaque PsoriasisLEO Pharma · NCT05919082 · 604 enrolled · China
- Jun 23, 2023Egymedicalpedia’s first study: no phase study in Alopecia AreataNew to EgymedicalpediaEgymedicalpedia · NCT05954104 · 80 enrolled · Egypt
- Dec 11, 2025Huadong Medicine’s first study: phase 3 study in Plaque PsoriasisNew to Huadong MedicineHuadong Medicine · NCT07357831 · 539 enrolled · China
TargetBeta
“Vitamin D receptor agonist”ChEMBL 37, by rule
Other programs on VDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Modified-release Calcifediol Capsulerule | OPKO Health | phase 3 | 10 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07357831Plaque Psoriasis · China | 3 | Completed | Huadong Medicine | Aug 6, 2026 | 539 |
| NCT05954104Alopecia Areata · Egypt | – | Completed | Egymedicalpedia | Oct 1, 2023 | 80 |
| NCT05919082Stable Plaque Psoriasis · China | 3 | Completed | LEO Pharma | Feb 23, 2024 | 604 |
| NCT03898583Psoriasis Vulgaris · Germany | 1 | Completed | LEO Pharma | Oct 29, 2019 | 15 |
| NCT03819218Psoriasis Vulgaris · Czechia, Germany | 2 | Terminated | MC2 Therapeutics | Dec 11, 2020 | 7 |
| NCT03802344Psoriasis Vulgaris · Czechia, Germany | 3 | Completed | MC2 Therapeutics | Oct 2, 2019 | 498 |
| NCT03758365Vasoconstriction · France | 1 | Completed | MC2 Therapeutics | Nov 23, 2018 | 36 |
| NCT03462927Psoriasis Vulgaris · United States | 2 | Completed | MC2 Therapeutics | Aug 4, 2018 | 63 |
| NCT03331523Scalp Psoriasis · United States | 3 | Completed | Glenmark Pharmaceuticals Ltd. India | Oct 25, 2018 | 643 |
| NCT03308799Psoriasis Vulgaris · United States | 3 | Completed | MC2 Therapeutics | Jun 8, 2018 | 794 |
| NCT03122353Scalp Psoriasis · United States | 1 | Completed | Tolmar | Nov 15, 2017 | 699 |
| NCT03079973Nail Psoriasis · United States | 3 | Withdrawn | Almirall | Jul 2018 | 0 |
| NCT02606760Nail Psoriasis · Bulgaria, Czechia, Germany and more | 3 | Completed | Almirall | Feb 8, 2017 | 378 |
| NCT02387853Psoriasis Vulgaris · United States, Netherlands, Poland and more | 2 | Completed | LEO Pharma | Mar 28, 2018 | 117 |
| NCT01935869Psoriasis Vulgaris · France | 1 | Completed | LEO Pharma | Nov 2013 | 224 |
| NCT01866163Psoriasis Vulgaris · United States | 3 | Completed | LEO Pharma | Oct 2013 | 426 |
| NCT01600222Psoriasis Vulgaris · Canada | 2 | Completed | LEO Pharma | May 2013 | 37 |
| NCT01582932Psoriasis · United States | 1 | Completed | Mayne Pharma International Pty | Aug 2018 | 36 |
| NCT01563068Psoriasis · United States | 1 | Completed | Mayne Pharma International Pty | Aug 2015 | 18 |
| NCT01536938Psoriasis Vulgaris · United States | 2 | Completed | LEO Pharma | Sep 2012 | 303 |
| NCT01536886Psoriasis Vulgaris · United States | 2 | Completed | LEO Pharma | Sep 2012 | 376 |
| NCT01188928Psoriasis Vulgaris · United States | 3 | Completed | LEO Pharma | Mar 2011 | 1,152 |
| NCT01139580Psoriasis · United States | 3 | Completed | GlaxoSmithKline | Dec 2010 | 363 |
| NCT00817219Psoriasis Vulgaris · United States | 2 | Completed | LEO Pharma | Dec 2011 | 33 |
| NCT00704262Psoriasis Vulgaris · United States, Canada, Germany and more | 2 | Completed | LEO Pharma | Dec 2009 | 33 |
| NCT00691002Psoriasis Vulgaris · Croatia, Germany, Poland and more | 3 | Completed | LEO Pharma | Jan 2010 | 1,245 |
| NCT00670241Psoriasis Vulgaris · Canada | 3 | Completed | LEO Pharma | Feb 2009 | 458 |
| NCT00640822Psoriasis Vulgaris · Canada, France, United Kingdom | 3 | Completed | LEO Pharma | Jun 2009 | 782 |
| NCT00574249Psoriasis · Austria, Belgium, Czech Republic and more | 3 | Completed | Abbott | Oct 2008 | 730 |
| NCT00279162Psoriasis · United States | 3 | Completed | LEO Pharma | 160 | |
| NCT00263718Psoriasis Vulgaris · Canada, Germany, Ireland and more | 2 | Completed | LEO Pharma | 360 | |
| NCT00248456Psoriasis Vulgaris · China | 4 | Completed | LEO Pharma | 320 | |
| NCT00243464Psoriasis of Scalp · Belgium, Canada, Denmark and more | 3 | Completed | LEO Pharma | 300 | |
| NCT00216892Psoriasis Vulgaris · Belgium, Canada, France and more | 4 | Completed | LEO Pharma | 1,032 | |
| NCT00216879Psoriasis of Scalp · Canada, Denmark, France and more | 3 | Completed | LEO Pharma | 800 | |
| NCT00216840Psoriasis of Scalp · Belgium, Canada, Finland and more | 3 | Completed | LEO Pharma | 1,350 | |
| NCT00216827Psoriasis of Scalp · Canada, Denmark, France and more | 3 | Completed | LEO Pharma | 1,485 |
How it is read
Names in the registry
- “LEO 90100”, 7 entries
- “MC2-01 cream”, 4 entries
- “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
- “Calcipotriol plus hydrocortisone (LEO 80190)”, 2 entries
- “MC2-01 Cream”, 2 entries
Codes read as this program: P3073.
Conditions, from the studies’ own filings
- Psoriasis, 37 studies
- Alopecia Areata, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.